US Heart Pump Devices Market Research Report: Size, Share, Trend Analysis By Product (Ventricular Assist Devices, Left Ventricular Assist Devices, Right Ventricular Assist Devices, Bi- Ventricular Assist Devices, Percutaneous Ventricular Assist Devices, Transcutaneous Ventricular Assist Devices, Intra-Aortic Balloon Pumps, Total Artificial Heart), By Device Type (Implantable Heart Pump Devices, Extracorporeal Heart Pump Devices), By Therapy (Bridge-to-candidacy (BTC), Bridge-to-transplant (BTC), Destination Therapy (DT), Others) and By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Research Institutes, Others) - Growth Outlook & Industry Forecast 2025 To 2035
As per Market Research Future analysis, the US heart pump-devices market Size was estimated at 207.52 USD Million in 2024. The US heart pump-devices market is projected to grow from 224.67 USD Million in 2025 to 496.85 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.2% during the forecast period 2025 - 2035
The US heart pump-devices market is experiencing robust growth driven by technological advancements and increasing healthcare investments.
| 2024 Market Size | 207.52 (USD Million) |
| 2035 Market Size | 496.85 (USD Million) |
| CAGR (2025 - 2035) | 8.26% |
Abbott (US), Medtronic (US), Boston Scientific (US), Terumo (JP), Cleveland Heart (US), CardiacAssist (US), Syncardia (US), Getinge (SE), LivaNova (GB)
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The heart pump-devices market is currently experiencing notable advancements driven by technological innovations and increasing prevalence of cardiovascular diseases. The integration of artificial intelligence and machine learning into device functionality appears to enhance patient outcomes and streamline clinical workflows. Furthermore, the growing emphasis on minimally invasive procedures is likely to propel the adoption of these devices, as they offer reduced recovery times and lower risks of complications. Regulatory bodies are also playing a crucial role in ensuring the safety and efficacy of new devices, which may foster greater confidence among healthcare providers and patients alike. In addition, the heart pump-devices market is witnessing a shift towards personalized medicine, where devices are tailored to meet individual patient needs. This trend is supported by ongoing research and development efforts aimed at improving device performance and compatibility with various patient profiles. As the healthcare landscape evolves, the demand for innovative solutions that address specific cardiovascular conditions is expected to rise, potentially leading to a more competitive market environment. Overall, the heart pump-devices market is poised for growth, driven by technological advancements and a focus on patient-centered care.
Recent innovations in heart pump-devices are transforming treatment options. Enhanced functionalities, such as remote monitoring and data analytics, are becoming more prevalent. These advancements may improve patient management and outcomes.
There is a growing trend towards minimally invasive techniques in the heart pump-devices market. Such procedures are associated with shorter recovery times and reduced complications, making them increasingly attractive to both patients and healthcare providers.
The shift towards personalized medicine is influencing the heart pump-devices market. Devices are being developed to cater to individual patient needs, which may enhance treatment efficacy and patient satisfaction.
Innovations in the design and functionality of heart pump devices are driving growth in the heart pump-devices market. Recent advancements include the development of smaller, more efficient devices that can be implanted with minimal invasiveness. These innovations not only enhance patient comfort but also improve recovery times, making them more appealing to both patients and healthcare providers. The heart pump-devices market is likely to benefit from these technological breakthroughs, as they may lead to increased adoption rates among clinicians. As a result, the market could witness a compound annual growth rate (CAGR) of approximately 10% through 2028.
The increasing incidence of cardiovascular diseases in the US is a primary driver for the heart pump-devices market. According to the CDC, heart disease remains the leading cause of death, accounting for approximately 697,000 deaths annually. This alarming statistic underscores the urgent need for effective treatment options, including heart pump devices. As the population ages, the prevalence of conditions such as heart failure is expected to rise, further propelling demand for innovative heart pump technologies. The heart pump-devices market is likely to experience substantial growth as healthcare providers seek advanced solutions to manage these chronic conditions, potentially leading to a market valuation exceeding $5 billion by 2027.
Public awareness campaigns focusing on heart health are becoming more prevalent in the US, which is positively influencing the heart pump-devices market. Organizations such as the American Heart Association are actively promoting education on cardiovascular health, leading to increased screening and early diagnosis of heart conditions. This heightened awareness is likely to result in a greater demand for heart pump devices as patients seek effective treatment options. The heart pump-devices market may see a surge in sales as more individuals become informed about available technologies, potentially increasing market penetration by 15% over the next few years.
Regulatory support for the approval of new heart pump devices is a crucial driver for the heart pump-devices market. The FDA has streamlined the approval process for innovative medical devices, allowing for faster access to market for new technologies. This regulatory environment encourages manufacturers to invest in research and development, leading to a wider array of heart pump options for patients. The heart pump-devices market is likely to expand as new products receive approval, potentially increasing competition and driving down costs. This supportive regulatory framework may result in a market growth trajectory that aligns with an annual increase of 7% in device availability.
Investment in healthcare infrastructure in the US is significantly impacting the heart pump-devices market. With the ongoing expansion of hospitals and specialized cardiac care centers, there is a growing demand for advanced medical devices. The American Hospital Association reports that hospitals are increasingly adopting cutting-edge technologies to enhance patient care. This trend is likely to drive the heart pump-devices market as healthcare facilities prioritize the acquisition of state-of-the-art equipment. Furthermore, government initiatives aimed at improving healthcare access and quality may lead to increased funding for cardiac care, potentially resulting in a market growth rate of around 8% annually over the next five years.
The US heart pump-devices market is characterized by a diverse range of products, with left ventricular assist devices (LVADs) holding the largest market share due to their widespread application and effectiveness in treating advanced heart failure. Other significant players include ventricular assist devices and intra-aortic balloon pumps, which contribute substantially but have smaller markets compared to LVADs. The positioning of these devices reflects the evolving needs of patients and healthcare providers in managing heart conditions. Growth trends in this segment are driven by technological advancements, increasing incidence of heart failure, and a strong push towards innovative treatment solutions. Ventricular assist devices are experiencing rapid adoption, particularly in patients awaiting heart transplants, marking them as the fastest-growing segment. Furthermore, the development of more compact and efficient devices is expected to enhance patient outcomes and attract funding for research and clinical applications.
Left Ventricular Assist Devices (Dominant) vs. Ventricular Assist Devices (Emerging)
Left ventricular assist devices are currently the dominant force in the US heart pump-devices market, primarily due to their critical role in managing severe heart failure and prolonging patient life. They have evolved significantly, featuring improved biocompatibility and usability, appealing to both clinicians and patients. Ventricular assist devices are emerging as key players, providing versatile options for temporary or long-term support in varying clinical scenarios. The innovations in design and functionality for both segments are paving the way for better outcomes and tailored therapies, making them indispensable in modern cardiac care.
In the US heart pump-devices market, implantable heart pump devices hold a significant share, dominating the segment with their advanced technology and efficacy in long-term heart failure management. Meanwhile, extracorporeal heart pump devices, while smaller in market share, are gaining traction due to their effective short-term applications and the increasing number of surgical procedures requiring temporary cardiac support. The growth trends for both segments are influenced by technological advancements and rising awareness regarding heart diseases. Implantable devices benefit from an aging population and the escalating incidence of coronary artery diseases. Conversely, extracorporeal devices are becoming the fastest-growing segment propelled by innovations and their use during complex surgeries, leading to broader acceptance and clinical application.
Implantable heart pump devices (Dominant) vs. Extracorporeal heart pump devices (Emerging)
Implantable heart pump devices are considered the dominant technology in the market due to their ability to provide effective long-term support for patients with severe heart failure. These devices offer a range of configurations, including ventricular assist devices (VADs) which are designed to improve heart function and enhance patients' quality of life. On the other hand, extracorporeal heart pump devices are classified as emerging technologies, primarily used for short-term support in critical care settings. Their versatility and advancements in design make them ideal for acute cases and surgical interventions, connecting them to a rapid growth trajectory as healthcare providers increasingly adopt these devices for temporary cardiac assistance.
In the US heart pump-devices market, the therapy segment comprises several key categories, each with distinct market dynamics. Destination therapy (DT) currently holds the largest share, largely due to its established role in providing long-term support for patients with advanced heart failure. In contrast, the Bridge-to-candidacy (BTC) and Bridge-to-transplant (BTC) segments, while significant, have smaller shares but are critical for facilitating treatment paths for patients awaiting transplants. The Others category includes innovative therapies that are slowly gaining traction in the market.
Destination therapy (Dominant) vs. Bridge-to-transplant (Emerging)
The Destination therapy (DT) segment is characterized by its focus on providing a long-term solution for patients with end-stage heart failure, offering a viable alternative to heart transplantation. It is widely regarded as a dominant choice due to its comprehensive support mechanisms, including improved patient quality of life and extended survival rates. On the other hand, the Bridge-to-transplant (BTC) segment is emerging rapidly as advancements in technology and clinical protocols enhance its effectiveness. This increasing acceptance is driven by a growing patient population and an expanding donor organ shortage, which motivates the use of devices that sustain patients until they are eligible for transplants. Both segments play crucial roles in the overall treatment landscape, catering to the varying needs of heart failure patients.
In the US heart pump-devices market, Hospitals & Clinics hold the largest share among the end-user segments, indicating their critical role in patient care and advanced medical treatments. In comparison, Ambulatory Surgical Centers are rapidly increasing their market presence, driven by the rising preference for outpatient procedures and minimally invasive techniques, which enhances patient recovery times. Growth trends for this segment are boosted by technological advancements in heart pump devices, increasing prevalence of cardiovascular diseases, and a shift towards outpatient care. Research institutes are also contributing to innovation through studies and trials, while the 'Others' category includes various healthcare settings where heart pump devices are being adopted, reflecting a broader acceptance across different healthcare services.
Hospitals & Clinics (Dominant) vs. Ambulatory Surgical Centers (Emerging)
Hospitals & Clinics dominate the US heart pump-devices market due to their comprehensive care capabilities and access to cutting-edge technology. These facilities are equipped with the latest heart pump devices and maintain a high operational volume, providing continuous care for patients with severe cardiac conditions. On the other hand, Ambulatory Surgical Centers are emerging as a key player, offering patients personalized care in a cost-effective manner. They focus on outpatient procedures, providing convenience and shorter recovery times. This segment's evolution is attributed to shifting healthcare policies favoring outpatient services and the increasing patient demand for minimally invasive options, positioning them as a significant growth driver in the overall market.
Get more detailed insights about US Heart Pump Devices Market Request Free Sample
The heart pump-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of cardiovascular diseases. Major players such as Abbott (US), Medtronic (US), and Boston Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott (US) focuses on innovation, particularly in developing next-generation heart pumps that integrate advanced monitoring technologies. Medtronic (US) emphasizes strategic partnerships and acquisitions to bolster its product portfolio, while Boston Scientific (US) is investing heavily in research and development to expand its offerings in minimally invasive heart pump solutions. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and patient-centric solutions.Key business tactics within the heart pump-devices market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a diverse range of products and innovations, fostering competition that drives advancements in technology and patient care.
In October Abbott (US) announced the launch of its latest heart pump device, which features enhanced biocompatibility and a streamlined design aimed at improving patient outcomes. This strategic move is significant as it not only reinforces Abbott's commitment to innovation but also positions the company to capture a larger share of the growing market for advanced heart pump technologies. The introduction of this device is likely to attract attention from healthcare providers seeking cutting-edge solutions for heart failure patients.
In September Medtronic (US) completed the acquisition of a promising startup specializing in AI-driven cardiac monitoring systems. This acquisition is pivotal as it allows Medtronic to integrate artificial intelligence into its heart pump devices, potentially enhancing patient monitoring and outcomes. The strategic importance of this move lies in Medtronic's ability to leverage AI technology to differentiate its products in a competitive market, aligning with the broader trend of digital transformation in healthcare.
In August Boston Scientific (US) entered into a collaboration with a leading research institution to develop next-generation heart pump technologies. This partnership is crucial as it underscores Boston Scientific's commitment to innovation through collaboration, enabling the company to access cutting-edge research and accelerate the development of new products. Such strategic alliances are becoming increasingly important in the heart pump-devices market, as they facilitate knowledge sharing and resource pooling among industry players.
As of November current competitive trends in the heart pump-devices market are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are shaping the landscape, allowing companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, reliability in supply chains, and the ability to deliver superior patient outcomes. This shift indicates a growing emphasis on innovation and quality as key drivers of success in the heart pump-devices market.
Recent developments in the US Heart Pump Devices Marketindicate significant advancements and activities among key players such as Medtronic, Abbott, and Boston Scientific. In September 2023, Medtronic announced its new heart pump technology aimed at improving patient outcomes for severe heart failure, reflecting ongoing innovation in the sector. Additionally, Abbott has been making strides with its recent clinical trials targeting advanced heart failure treatments, showcasing the critical shift towards less invasive solutions.
In the mergers and acquisitions landscape, Asahi Kasei acquired a majority stake in a significant heart pump technology company in August 2023, enhancing its position in the market. Furthermore, Boston Scientific completed the acquisition of a startup specializing in heart pump devices in July 2023, which is anticipated to bolster its R&D capabilities.
Over the last 2-3 years, the US Heart Pump Devices Market has witnessed a noted increase in valuation due to rising patient needs and advances in technology, with the market expected to grow substantially as more companies focus on developing innovative solutions for heart failure management. These developments underscore the dynamic nature of the market and the potential for continued growth driven by innovation and strategic partnerships.
The Heart Pump Devices Market is projected to grow at an 8.26% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.
New opportunities lie in:
By 2035, the heart pump-devices market is expected to achieve substantial growth and innovation.
| MARKET SIZE 2024 | 207.52(USD Million) |
| MARKET SIZE 2025 | 224.67(USD Million) |
| MARKET SIZE 2035 | 496.85(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.26% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott (US), Medtronic (US), Boston Scientific (US), Terumo (JP), Cleveland Heart (US), CardiacAssist (US), Syncardia (US), Getinge (SE), LivaNova (GB) |
| Segments Covered | Product, Device Type, Therapy, End-User |
| Key Market Opportunities | Advancements in minimally invasive heart pump-devices enhance patient outcomes and expand market potential. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the heart pump-devices market, enhancing patient outcomes. |
| Countries Covered | US |
The market valuation was $207.52 Million in 2024.
The projected valuation for 2035 is $496.85 Million.
The expected CAGR is 8.26% during the forecast period 2025 - 2035.
Key players include Abbott, Medtronic, Boston Scientific, Terumo, Cleveland Heart, CardiacAssist, Syncardia, Getinge, and LivaNova.
Main product segments include Ventricular assist devices, Left ventricular assist devices, Right ventricular assist devices, Bi-ventricular assist devices, and others.
The valuation of implantable heart pump devices was $124.52 Million in 2024.
The expected market size for destination therapy is projected to reach $250 Million by 2035.
Hospitals and clinics contributed $80.0 Million to $190.0 Million in 2024.
The valuation range for percutaneous ventricular assist devices is between $15.0 Million and $35.0 Million.
The total artificial heart segment is expected to grow from $17.52 Million to $36.85 Million by 2035.
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
